Is Bio-Techne (TECH) Reasonable On Cash Flow Or Too Rich?

Bio-Techne has seen a mixed share-price story, with a sizeable setback over longer periods but a much stronger picture over the past year. This puts the focus squarely on what investors are really paying for its cash flows. With the stock around US$72.34, the key issue is how well that price lines up with the cash the business can generate over time.

• The share price has fallen 44.2% over 5 years, which raises the question of whether the market has reset expectations for Bio-Techne's future cash generation or is simply marking time until the underlying cash flows catch up.
• The company relies on turning its life sciences tools and diagnostics portfolio into steady, repeatable cash inflows, which can shape how investors think about the timing and durability of those cash flows that feed into any intrinsic value estimate.
• What if you looked at Bio-Techne through its earnings instead? See what Bio-Techne's 62.4x P/E says about the price.

The issue now is whether Bio-Techne's current share price can be explained by the cash flows that underpin its intrinsic value estimate using a Discounted Cash Flow (DCF) approach.

If you want to stress test the same cash flow question beyond Bio-Techne, line it up against other companies using the 34 high quality undervalued stocks

Has Bio-Techne Run Too Far on Cash Flow?

The Discounted Cash Flow (DCF) method here focuses on the cash Bio-Techne can generate for shareholders over time. On the latest twelve month view, the business produced roughly $250.6 million of free cash flow, and the model assumes that this pool of cash increases over the coming decade before easing into a slower second stage.

For Bio-Techne, the key point is that this 2 Stage Free Cash Flow to Equity model treats the company as a growing cash generator that eventually matures, rather than a turnaround or shrinking operation. Even with those growing projections, the DCF output still puts the estimated intrinsic value meaningfully below the current share price of $72.34. This suggests the market is already attaching a rich price to those future cash flows. Find out what Bio-Techne could be worth using our Discounted Cash Flow (DCF) estimate.

The Bio-Techne Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where this valuation puzzle for Bio-Techne leaves off. They spell out which paths for growth, profitability and earnings would need to play out for the stock to look materially cheaper or more expensive than today's price, using Bio-Techne's Community page as home base. Each narrative turns fair value into a specific thesis about the business that can be tracked over time and checked against what actually happens.

Bio-Techne followers are largely debating how much more potential the current business mix and deal news really justify at today’s price.

Bull case: roughly fairly valued

"With 80% of revenue from recurring consumables, including recent partnerships in high-value diagnostic biomarkers and a sharpened focus on portfolio diversification through targeted M&A, Bio-Techne is uniquely positioned to compound both revenue and free cash flow growth…"

Discover why this Narrative puts Bio-Techne at roughly fairly valued.

Bear case: roughly fairly valued

"Heightened competition from larger, diversified life science tools companies and increasing commoditization of core reagents and instruments puts ongoing pressure on pricing and market share…"

Explore why this Narrative puts Bio-Techne at roughly fairly valued.

Bio-Techne’s price is only one piece of the decision

Valuation models tell you what you are paying for Bio-Techne’s cash flows, but the people steering that cash engine and the way their pay packets are structured can tilt the whole risk and reward profile. See who runs Bio-Techne and how they are paid.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com